415 results on '"Vachhani, Pankit"'
Search Results
2. Consistency of Spleen and Symptom Reduction Regardless of Cytopenia in Patients With Myelofibrosis Treated With Pacritinib
3. SOHO State of the Art Updates and Next Questions | Diagnosis, Outcomes, and Management of Prefibrotic Myelofibrosis
4. A novel application of XPO1 inhibition for the treatment of myelofibrosis
5. Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia
6. Impact of induction intensity and transplantation on outcomes of patients with complex karyotype and TP53-mutated acute myeloid leukemia
7. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
8. Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis
9. How the COVID-19 Pandemic Reshaped the Management of Leukemia and Affected Patient Outcomes
10. Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML
11. Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia
12. Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditis
13. Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approval
14. In-depth analysis of responders in the phase 3 PhALLCON trial of ponatinib vs imatinib in newly diagnosed Ph+ ALL.
15. A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify).
16. Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
17. Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study
18. Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia
19. A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia
20. Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis
21. Outcomes of high-risk acute promyelocytic leukemia patients treated with arsenic trioxide (ATO)/all trans retinoic acid (ATRA) based induction and consolidation without maintenance phase: A case Series
22. Observation Versus Immediate Reinduction for Acute Myeloid Leukemia Patients With Indeterminate Day 14 Bone Marrow Results
23. Interferons in the treatment of myeloproliferative neoplasms
24. Ruxolitinib for myelofibrosis: The earlier, the better?
25. Idarubicin and cytarabine with and without midostaurin for FLT3-mutated acute myeloid leukemia.
26. Contributors
27. Cardivascular Toxicities of Immunotherapy
28. Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience
29. POSTER: ALL-300 First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia
30. POSTER: MPN-559 Bromodomain and Extra-terminal (BET) Inhibitor INCB057643 (LIMBER-103) in Patients With Relapsed or Refractory Myelofibrosis (R/R MF) and Other Advanced Myeloid Neoplasms: A Phase I Study
31. MPN-339 Outcomes of Patients With Myelofibrosis and Elevated Peripheral Blood Blasts Treated With Pacritinib on Phase II/III Trials
32. MPN-559 Bromodomain and Extra-Terminal (BET) Inhibitor INCB057643 (LIMBER-103) in Patients With Relapsed or Refractory Myelofibrosis (R/R MF) and Other Advanced Myeloid Neoplasms: A Phase I Study
33. MPN-524 Reductions in Indolent Systemic Mastocytosis Biomarker Burden With Avapritinib in the Registrational, Double-Blind, Placebo-Controlled PIONEER Trial
34. POSTER: MPN-339 Outcomes of Patients With Myelofibrosis and Elevated Peripheral Blood Blasts Treated With Pacritinib on Phase II/III Trials
35. POSTER: MDS-460 Efficacy of Pacritinib for Spleen, Symptoms, and Anemia Benefit in Myelofibrosis Patients Across the Cytopenic Spectrum
36. Oral Abstract: ALL-300 First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia
37. MDS-460 Efficacy of Pacritinib for Spleen, Symptoms, and Anemia Benefit in Myelofibrosis Patients Across the Cytopenic Spectrum
38. ALL-300 First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia
39. POSTER: MPN-524 Reductions in Indolent Systemic Mastocytosis Biomarker Burden With Avapritinib in the Registrational, Double-Blind, Placebo-Controlled PIONEER Trial
40. Post‐remission cytopenia management in patients with AML treated with venetoclax in combination with hypomethylating agents: Pre‐ versus post‐VIALE‐A real‐world experience from a predominantly US community setting
41. P1037: CONSISTENCY OF PACRITINIB FOR SPLEEN AND SYMPTOM REDUCTION IN PATIENTS WITH MYELOFIBROSIS REGARDLESS OF CYTOPENIAS
42. S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS)
43. P1017: REDUCTIONS IN INDOLENT SYSTEMIC MASTOCYTOSIS BIOMARKER BURDEN WITH AVAPRITINIB IN THE REGISTRATIONAL, DOUBLE-BLIND PLACEBO-CONTROLLED PIONEER TRIAL
44. PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF)
45. S115: CONSOLIDATION WITH BLINATUMOMAB IMPROVES OVERALL AND RELAPSE-FREE SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: IMPACT OF AGE AND MRD LEVEL IN ECOG-ACRIN E1910
46. P1055: BROMODOMAIN AND EXTRA-TERMINAL (BET) INHIBITOR INCB057643 (LIMBER-103) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MYELOFIBROSIS (R/R MF) AND OTHER ADVANCED MYELOID NEOPLASMS: A PHASE 1 STUDY
47. S110: PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL
48. Dexrazoxane for cardioprotection in older adults with acute myeloid leukemia
49. Cardiovascular Toxicities Related to Immune Checkpoint Inhibitors
50. Avapritinib versus Placebo in Indolent Systemic Mastocytosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.